Business
Sandoz further asserts leadership in biosimilars, breaking ground on new Slovenia facility to expand European biosimilar hub and global market reach
MEDIA RELEASE Investment marks latest step in strategic plan to capture significant part of unprecedented biosimilar patent-expiry market opportunity of USD 222 billion over next 10 yearsOngoing investment in in-house manufacturing to create end-to-end leading European biosimilar hub, capital expenditure commitments remain unchangedMost recent USD 440 million investment in new production plant in Brnik, due to open in 2028, brings total planned investment in Slovenia to more than USD 1.1 billion
About this update from Sandoz Group Ltd
[{"type":"image","alt":"Sandoz Group","displaySize":"","headline":null,"caption":"Sandoz Group","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":41,"url":"https://media.zenfs.com/en/globenewswire.com/f12e92daa0852ddf107832c313b07d25"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/qaCYsKqoASJVSMd1vUCp9Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTU3O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/f12e92daa0852ddf107832c313b07d25","width":300,"height":41}},"lazy":false},{"type":"text","content":"MEDIA RELEASE","length":13,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Investment marks latest step in strategic plan to capture significant part of unprecedented biosimilar patent-expiry market opportunity of USD 222 billion over next 10 years","length":173,"tagName":"p"}]},{"val":[{"type":"text","content":"Ongoing investment in in-house manufacturing to create end-to-end leading European biosimilar hub, capital expenditure commitments remain unchanged","length":147,"tagName":"p"}]},{"val":[{"type":"text","content":"Most recent USD 440 million investment in new production plant in Brnik, due to open in 2028, brings total planned investment in Slovenia to more than USD 1.1 billion by 2029","length":174,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":494,"olType":false},{"type":"text","content":"Basel, July 1, 2025 – Sandoz (SIX:SDZ/OTCQX:SDZNY), the global leader in generic and biosimilar medicines, today announced the start of construction for a new, state-of-the-art biosimilars production center for sterile product manufacturing in Brnik, Slovenia. This USD 440 million project brings the company’s total planned and ongoing investment in Slovenia to more than USD 1.1 billion by 2029. It complements ongoing investments in Slovenia, namely a new biosimilar drug substance production center in Lendava and a biosimilar development center in Ljubljana.","length":563,"tagName":"p"},{"type":"text","content":"The construction start on the new plant marks the latest development in the company’s strategic plan to capture a significant part of an unprecedented market opportunity, with the value of biosimilar patent expiries expected to reach USD 222 billion[1] over the next 10 years. The ongoing investments in in-house capabilities to establish a fully integrated European biosimilar hub are in...